PMID- 33423957
OWN - NLM
STAT- MEDLINE
DCOM- 20220114
LR  - 20220114
IS  - 2213-2945 (Print)
IS  - 2213-2953 (Linking)
VI  - 10
IP  - 3
DP  - 2021 May-Jun
TI  - Oncogenic gene transcripts detection by FISH on liquid-based cytology slides of 
      338 advanced lung cancer patients.
PG  - 270-277
LID - S2213-2945(20)30330-6 [pii]
LID - 10.1016/j.jasc.2020.12.002 [doi]
AB  - INTRODUCTION: Oncogenic gene transcripts in advanced lung cancer are a strong 
      indication for targeted therapy. Cytology specimens are often the only materials 
      available for oncogenic fusion analysis. This prospective study is to evaluate 
      the feasibility of anaplastic lymphoma kinase (ALK) gene rearrangements, ROS 
      oncogene 1 (ROS-1), and c-mesenchymal-epidermal transformation (c-MET) detected 
      by fluorescence in situ hybridization (FISH) using liquid-based cytology (LBC) 
      slides. MATERIALS AND METHODS: Consecutive cytology specimens including 
      fine-needle aspiration biopsy (FNAB) and serous effusions from 338 advanced lung 
      cancer patients were collected between March 1, 2015, and July 6, 2016. The 
      correlation between ALK, ROS-1, c-MET, and other common driver gene abnormalities 
      and the therapeutic response to crizotinib in ALK-positive patients were also 
      evaluated. RESULTS: ALK fusion transcripts were detected in 31 of 338 patients 
      (9.17%). Twenty-two of the 31 ALK-positive patients were treated with crizotinib 
      at our institution (2 were lost to follow-up), and the overall response rate was 
      75.0 % (15 of 20); disease control rate was 90.0% (18 of 20). FISH analyses for 
      ROS-1 and c-MET were performed on 75 and 73 patients, respectively, and showed 3 
      patients positive for ROS-1 and 3 positive for c-MET. These positive cases were 
      all ALK-negative. CONCLUSION: For patients with advanced lung cancer, LBC slides 
      are suitable for detecting oncogenic gene transcripts, and the results can 
      provide a reliable guideline for targeted therapy.
CI  - Copyright (c) 2021 American Society of Cytopathology. Published by Elsevier Inc. 
      All rights reserved.
FAU - Jia, Jia
AU  - Jia J
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Guo, HuiQin
AU  - Guo H
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Zhao, Huan
AU  - Zhao H
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Zhao, LinLin
AU  - Zhao L
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Ling, Yun
AU  - Ling Y
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Chen, Longwen
AU  - Chen L
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, 
      Arizona. Electronic address: chen.longwen@mayo.edu.
FAU - Zhang, ZhiHui
AU  - Zhang Z
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China. Electronic address: Zhangzhh9@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201216
PL  - United States
TA  - J Am Soc Cytopathol
JT  - Journal of the American Society of Cytopathology
JID - 101613234
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase/*genetics
MH  - Biopsy, Fine-Needle
MH  - Crizotinib/*therapeutic use
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lung Neoplasms/*drug therapy/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - *Oncogenes
MH  - Prospective Studies
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/*genetics
MH  - Proto-Oncogene Proteins/*genetics
MH  - Proto-Oncogene Proteins c-met/*genetics
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - ALK
OT  - Liquid-based cytology
OT  - Lung cancer
OT  - ROS-1
OT  - c-MET
EDAT- 2021/01/12 06:00
MHDA- 2022/01/15 06:00
CRDT- 2021/01/11 05:27
PHST- 2020/11/09 00:00 [received]
PHST- 2020/12/03 00:00 [revised]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2022/01/15 06:00 [medline]
PHST- 2021/01/11 05:27 [entrez]
AID - S2213-2945(20)30330-6 [pii]
AID - 10.1016/j.jasc.2020.12.002 [doi]
PST - ppublish
SO  - J Am Soc Cytopathol. 2021 May-Jun;10(3):270-277. doi: 10.1016/j.jasc.2020.12.002. 
      Epub 2020 Dec 16.